Alteogen Eyes ASEAN, OIC Biosimilar Markets Via Malaysian JV

 
• By Jung Won Shin

Alteogen is taking a different strategy versus its bigger South Korean biosimilar rivals as it is aiming to enter the ASEAN and OIC biosimilar markets by establishing a joint venture with a state-owned Malaysian firm.

Business teamwork puzzle pieces.

More from Business

More from Scrip